StockData

Dianthus Therapeutics, Inc. (DNTH) stock

DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$86.98−2.57 (-2.87%)

Close on Nov 17, 2026Market cap $4.87BP/E –Yield 0.00%

Dianthus Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Dianthus Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$236.03M. For fiscal 2025 it was -$177.93M. The highest annual figure on record is -$9.27M in fiscal 2016.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$177.93M–
FY2024Dec 31, 2024-$101.86M–
FY2023Dec 31, 2023-$48.17M–
FY2022Dec 31, 2022-$29.71M–
FY2021Dec 31, 2021-$74.69M–
FY2020Dec 31, 2020-$78.70M–
FY2019Dec 31, 2019-$82.97M–
FY2018Dec 31, 2018-$59.96M–
FY2017Dec 31, 2017-$35.73M–
FY2016Dec 31, 2016-$9.27M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$58.47M–
Q2 FY2026Jun 30, 2026-$61.48M–
Q1 FY2026Mar 31, 2026-$46.53M–
Q4 FY2025Dec 31, 2025-$69.54M–
Q3 FY2025Sep 30, 2025-$40.29M–
Q2 FY2025Jun 30, 2025-$34.93M–
Q1 FY2025Mar 31, 2025-$33.18M–
Q4 FY2024Dec 31, 2024-$31.92M–
Q3 FY2024Sep 30, 2024-$29.90M–
Q2 FY2024Jun 30, 2024-$22.20M–
Q1 FY2024Mar 31, 2024-$17.84M–
Q4 FY2023Dec 31, 2023-$12.96M–
Q3 FY2023Sep 30, 2023-$15.76M–
Q2 FY2023Jun 30, 2023-$11.78M–
Q1 FY2023Mar 31, 2023-$7.68M–
Q4 FY2022Dec 31, 2022-$10.69M–
Q3 FY2022Sep 30, 2022-$8.25M–
Q2 FY2022Jun 30, 2022-$18.08M–
Q1 FY2022Mar 31, 2022-$23.83M–
Q4 FY2021Dec 31, 2021-$20.14M–
Q3 FY2021Sep 30, 2021-$18.25M–
Q2 FY2021Jun 30, 2021-$17.61M–
Q1 FY2021Mar 31, 2021-$18.70M–
Q4 FY2020Dec 31, 2020-$19.07M–
Q3 FY2020Sep 30, 2020-$18.38M–
Q2 FY2020Jun 30, 2020-$20.01M–
Q1 FY2020Mar 31, 2020-$21.24M–
Q4 FY2019Dec 31, 2019-$24.64M–
Q3 FY2019Sep 30, 2019-$22.64M–
Q2 FY2019Jun 30, 2019-$19.34M–
Q1 FY2019Mar 31, 2019-$16.35M–
Q4 FY2018Dec 31, 2018-$17.93M–
Q3 FY2018Sep 30, 2018-$16.70M–
Q2 FY2018Jun 30, 2018-$14.03M–
Q1 FY2018Mar 31, 2018-$11.31M–
Q4 FY2017Dec 31, 2017-$8.17M–
Q3 FY2017Sep 30, 2017-$7.02M–
Q2 FY2017Jun 30, 2017-$15.73M–
Q1 FY2017Mar 31, 2017-$4.81M–

More Dianthus Therapeutics figures

See a number that looks wrong?